TABLE 3.
Condition | Measure | Baseline | Module 1 | Module 2 | Module 3 | Postintervention |
---|---|---|---|---|---|---|
aRR (95% CI) | ||||||
ARTI overall | Any prescribing | Reference | 0.97 (0.93–1.01) | 0.84 (0.80–0.87) | 0.89 (0.86–0.93) | 0.92 (0.89–0.96) |
Viral ARTI | Any prescribing | Reference | 0.73 (0.59–0.90) | 0.57 (0.46–0.72) | 0.61 (0.50–0.74) | 0.62 (0.52–0.74) |
All pharyngitis | Any prescribing | Reference | 1.06 (0.99–1.12) | 0.87 (0.81–0.93) | 0.84 (0.78–0.91) | 0.96 (0.90–1.02) |
AOM | Second-line prescribing | Reference | 1.02 (0.87–1.19) | 0.69 (0.58–0.81) | 0.87 (0.75–0.99) | 0.78 (0.67–0.90) |
Streptococcal pharyngitis | Second-line prescribing | Reference | 0.74 (0.53–1.00) | 0.62 (0.45–0.84) | 0.37 (0.24–0.56) | 0.63 (0.46–0.87) |
Sinusitis | Second-line prescribing | Reference | 0.64 (0.45–0.91) | 0.47 (0.34–0.66) | 0.60 (0.45–0.80) | 0.49 (0.35–0.69) |
Fully engaged clinicians watched all available tutorials, webinars, and boosters and received feedback reports.